{"api_version": 1, "episode_id": "ep_thoughts_on_the_market_9e8a2a729045", "title": "The Real Drivers of GLP-1 Growth", "podcast": "Thoughts on the Market", "podcast_slug": "thoughts_on_the_market", "category": "finance", "publish_date": "2026-04-17T21:00:00+00:00", "audio_url": "https://pdst.fm/e/pscrb.fm/rss/p/rss.art19.com/episodes/b130c00b-4762-4e8f-a1a2-f9095f6254f1.mp3?rss_browser=BAhJIhdzaWduYWxzeW50aC1pbmdlc3QGOgZFVA%3D%3D--5ebdfb1a8b46ca09b25141903f5cb74dc0744ed6", "source_link": "https://art19.com/shows/thoughts-on-the-market", "cover_image_url": "https://content.production.cdn.art19.com/images/68/53/52/d0/685352d0-9248-46b0-99bc-96589e58c7da/17e395c4e66b1b71c451c38d72389ffaebc7784e20e8c3bea964dc0287434ef3475e93f6527b48a642d0d7a6a23943dcdef6c0b861481aed9ef54002b9f78b4d.jpeg", "summary": "The episode outlines five drivers of GLP-1 therapy adoption: oral formulations, Medicare access, lower out-of-pocket costs, global expansion, and therapeutic innovation beyond weight loss. It projects a $190B base-case global market by 2035, with 12% of 1.3B eligible patients treated, and highlights a potential 1-2% reduction in U.S. calorie consumption.", "key_takeaways": ["Only 6% of eligible U.S. obesity patients currently use GLP-1 therapies, indicating significant growth runway.", "Oral GLP-1s are driving expansion, with nearly 80% of users being new to the category.", "Medicare access and falling out-of-pocket costs (down to $120/month) are accelerating adoption, with employer coverage expected to reach 65% by 2027."], "best_for": ["investors in biotech and pharmaceuticals", "healthcare policy analysts", "market strategists tracking metabolic drugs"], "why_listen": "Investors get a structured, data-backed framework for forecasting the $190B+ GLP-1 market, grounded in access, cost trends, and clinical expansion.", "verdict": "must_listen", "guests": [], "entities": {}, "quotes": [], "chapters": [], "overall_score": 88.0, "score_breakdown": {"clarity": 92.0, "originality": 88.0, "actionability": 88.0, "technical_depth": 82.0, "recency_relevance": 85.0, "information_density": 90.0}, "score_evidence": {"clarity": "We see five drivers that are pushing the next phase of adoption. The first is a shift to oral medications.", "originality": "We estimate GLP adoption could reduce U.S. calorie consumption by about 1-2% by 2035, with ripple effects across consumer behavior.", "actionability": "Average monthly out-of-pocket costs have declined to about $120, down from $170 last year.", "technical_depth": "Our base case assumes roughly 12% of that population is treated by 2035, including about 30% penetration in the U.S.", "recency_relevance": "A new U.S. framework is opening these drugs to millions of older patients, with out-of-pocket costs potentially around $50 per month.", "information_density": "Only about 6% of eligible obesity patients in the U.S. are currently using GLP-1 therapies, and just 2 outside the U.S."}, "score_reasoning": {}, "scoring_confidence": 0.95, "transcript_available": true, "transcript_chars": 3950, "transcript_provider": "groq"}